Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Rhodanine as a privileged scaffold in drug discovery.

Tomasić T, Masic LP.

Curr Med Chem. 2009;16(13):1596-629. Review.

PMID:
19442136
2.

Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation.

Tomašić T, Peterlin Mašič L.

Expert Opin Drug Discov. 2012 Jul;7(7):549-60. doi: 10.1517/17460441.2012.688743. Epub 2012 May 19. Review.

PMID:
22607309
3.

The synthesis and SAR of rhodanines as novel class C beta-lactamase inhibitors.

Grant EB, Guiadeen D, Baum EZ, Foleno BD, Jin H, Montenegro DA, Nelson EA, Bush K, Hlasta DJ.

Bioorg Med Chem Lett. 2000 Oct 2;10(19):2179-82.

PMID:
11012024
4.

In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B.

Brvar M, Perdih A, Hodnik V, Renko M, Anderluh G, Jerala R, Solmajer T.

Bioorg Med Chem. 2012 Apr 15;20(8):2572-80. doi: 10.1016/j.bmc.2012.02.052. Epub 2012 Mar 3.

PMID:
22444877
5.

Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.

Mendgen T, Steuer C, Klein CD.

J Med Chem. 2012 Jan 26;55(2):743-53. doi: 10.1021/jm201243p. Epub 2012 Jan 11.

PMID:
22077389
6.

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID:
18193820
7.

Discovery of potent and selective rhodanine type IKKβ inhibitors by hit-to-lead strategy.

Song H, Lee YS, Roh EJ, Seo JH, Oh KS, Lee BH, Han H, Shin KJ.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5668-74. doi: 10.1016/j.bmcl.2012.06.088. Epub 2012 Jul 15.

PMID:
22858099
8.

Chemical proteomics-based drug design: target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins.

Ge X, Wakim B, Sem DS.

J Med Chem. 2008 Aug 14;51(15):4571-80. doi: 10.1021/jm8002284. Epub 2008 Jul 11.

PMID:
18616236
9.

Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors.

Ahn JH, Kim SJ, Park WS, Cho SY, Ha JD, Kim SS, Kang SK, Jeong DG, Jung SK, Lee SH, Kim HM, Park SK, Lee KH, Lee CW, Ryu SE, Choi JK.

Bioorg Med Chem Lett. 2006 Jun 1;16(11):2996-9. Epub 2006 Mar 10.

PMID:
16530413
10.

Smaller is better for antibiotic discovery.

Waldrop GL.

ACS Chem Biol. 2009 Jun 19;4(6):397-9. doi: 10.1021/cb900122j.

PMID:
19537754
11.

Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors.

Goodman KB, Bury MJ, Cheung M, Cichy-Knight MA, Dowdell SE, Dunn AK, Lee D, Lieby JA, Moore ML, Scherzer DA, Sha D, Suarez DP, Murphy DJ, Harpel MR, Manas ES, McNulty DE, Annan RS, Matico RE, Schwartz BK, Trill JJ, Sweitzer TD, Wang DY, Keller PM, Krawiec JA, Jaye MC.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):27-30. doi: 10.1016/j.bmcl.2008.11.033. Epub 2008 Nov 14.

PMID:
19058966
12.

Catechol-rhodanine derivatives: Specific and promiscuous inhibitors of Escherichia coli deoxyxylulose phosphate reductoisomerase (DXR).

Zinglé C, Tritsch D, Grosdemange-Billiard C, Rohmer M.

Bioorg Med Chem. 2014 Jul 15;22(14):3713-9. doi: 10.1016/j.bmc.2014.05.004. Epub 2014 May 14.

PMID:
24890653
13.

Expanding the scope of human DNA polymerase λ and β inhibitors.

Strittmatter T, Brockmann A, Pott M, Hantusch A, Brunner T, Marx A.

ACS Chem Biol. 2014 Jan 17;9(1):282-90. doi: 10.1021/cb4007562. Epub 2013 Nov 15.

PMID:
24171552
14.

Discovery of novel benzene 1,3-dicarboxylic acid inhibitors of bacterial MurD and MurE ligases by structure-based virtual screening approach.

Perdih A, Kovac A, Wolber G, Blanot D, Gobec S, Solmajer T.

Bioorg Med Chem Lett. 2009 May 15;19(10):2668-73. doi: 10.1016/j.bmcl.2009.03.141. Epub 2009 Apr 1.

PMID:
19369074
15.

Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size.

Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, Pei D.

J Med Chem. 2004 Sep 23;47(20):4941-9.

PMID:
15369398
16.

Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening.

Turk S, Kovac A, Boniface A, Bostock JM, Chopra I, Blanot D, Gobec S.

Bioorg Med Chem. 2009 Mar 1;17(5):1884-9. doi: 10.1016/j.bmc.2009.01.052. Epub 2009 Jan 29.

PMID:
19223185
17.

Small Molecule Inhibitors of Human DNA Polymerase λ.

Strittmatter T, Bareth B, Immel TA, Huhn T, Mayer TU, Marx A.

ACS Chem Biol. 2011 Apr 15;6(4):314-9. doi: 10.1021/cb100382m. Epub 2011 Jan 18.

PMID:
21194240
18.

Application of nearest-neighbor and cluster analyses in pharmaceutical lead discovery.

Stanton DT, Morris TW, Roychoudhury S, Parker CN.

J Chem Inf Comput Sci. 1999 Jan-Feb;39(1):21-7.

PMID:
9987851
19.

Discovery of new antitumoral and antibacterial drugs from brazilian plant extracts using high throughput screening.

Younes RN, Varella AD, Suffredii IB.

Clinics (Sao Paulo). 2007 Dec;62(6):763-8. Review.

PMID:
18318049
20.

Quinoline as a privileged scaffold in cancer drug discovery.

Solomon VR, Lee H.

Curr Med Chem. 2011;18(10):1488-508. Review.

PMID:
21428893

Supplemental Content

Support Center